Unsere Praxis bleibt vom 22.12.2018 bis zum 02.01.2019 geschlossen.
Ab dem 3.1.2019 sind wir gerne wieder für Sie da!
🕯🎄 Wir wünschen Ihnen frohe Weihnachtsfeiertage und alles Gute für 2019! 🎄🎉
Prof. Dr. med. Stephan Vavricka Prof. Dr. med. Stephan Vavricka

Prof. Dr. med. Stephan Vavricka

Facharzt für Innere Medizin und
Facharzt für Gastroenterologie FMH
Spez. Hepatologie
Fähigkeitsausweis ERCP (SGG)
Fähigkeitsausweis Abdomensonographie (SGUM)

Tätigkeitsschwerpunkt:

  • Gastroenterologie
  • Hepatologie
  • Innere Medizin
  • chronisch entzündliche Darmkrankheiten
  • Nahrungsmittelunverträglichkeiten

Sprachen:

  • Deutsch
  • Englisch
  • Französisch
  • Italienisch
  • Tschechisch

Berufliche Erfahrung

Seit 2017 Zentrum für Gastroenterologie und Hepatologie
2010-2017 Leiter der Abteilung für Gastroenterologie und Hepatologie, Stadtspital Triemli Zürich
2008-2009 Oberarzt Klinik für Gastroenterologie und Hepatologie Universitätsspital Zürich und Kantonsspital Winterthur
2007-2008 Oberarzt Klinik für Gastroenterologie und Hepatologie, Universitätsspital Basel
2004-2006 Assistenzarzt Klinik für Gastroenterologie und Hepatologie, Universitätsspital Zürich
2002-2003 Research Fellow, The Martin Boyers Laboratories, University of Chicago, USA
2002-2002 Research Fellow, Klinik für Gastroenterologie und Hepatologie, Universitätsspital Zürich
2001-2001 Assistenzarzt Klinik für Hämatologie und Innere Medizin, Universitätsspital Zürich
2000-2001 Research Fellow Klinische Pharmakologie und Toxikologie, Universitätsspital Zürich
2000-2000 Assistenzarzt Klinik für Innere Medizin, Universitätsspital Zürich
1998-1999 Assistenzarzt Klinik für Innere Medizin, Kantonsspital Winterthur
1996-1997 Assistenzarzt Fliegerärztliches Institut Dübendorf

Aus- & Weiterbildung

2015 Anerkennung zum Titularprofessor
2007 Venia legendi (Habilitation)

Führung & Management

2015 CAS Leadership in Organisationen des Gesundheitssystems, Bern
2010 CAS Finanzielle Führung, ZHAW Winterthur
2009 CAS Managementgrundlagen für ÄrztInnen und Führungspersonen im Gesundheitswesen

Mitgliedschaften

  • Schweizerische Gesellschaft für Gastroenterologie (SGG SSG)
  • Schweizerische Gesellschaft für Ernährung (SGE-SSN)
  • Schweizerische Gesellschaft für Ultraschall in der Medizin (SGUM)
  • Schweizerische Gesellschaft für Innere Medizin (SGIM)
  • Verbindung der Schweizer Ärzte (FMH)
  • ÄrzteGesellschaft des Kantons Zürich (AGZ)
  • ECCO (European Crohn's and Colitis Organisation)
  • American College of Gastroenterology (ACG)
  • American Gastroenterological Association (AGA)
  • Schweizerische Interessengemeinschaft für Zöliakie
  • Schweizerische Morbus Crohn/Colitis ulcerosa Vereinigung (SMCCV)
  • Schweizerische Interessengemeinschaft Histamin-Intoleranz (SIGHI)
  • AHA! Allergiezentrum Schweiz
  • Präsident von IBDnet
  • Vorstandsmitglied der Schweizerischen IBD Kohorte
  • Vorstandsmitglied vom Verein Zürcher Internisten
  • Mitglied der Gesundheitskomission FDP des Kantons Zürich und der Stadt Zürich
  • Expertenrat aha! Experte Allergiezentrum Schweiz
  • Vorstandsmitglied "Educational Comitee" der ECCO 2013-2015 und Guideline Committee 2016-2019

Publikationsverzeichnis

  1. Bähler C, Schoepfer AM, Vavricka SR, Brüngger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000891
  2. Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2017 Apr 27. doi: 10.1097/ MIB.0000000001109.
  3. Melhem H, Spalinger MR, Cosin-Roger J, Atrott K, Lang S, Wojtal KA, Vavricka SR, Rogler G, Frey-Wagner I. Prdx6 Deficiency Ameliorates DSS Colitis: Relevance of Compensatory Antioxidant Mechanisms. J Crohns Colitis. 2017 Feb 12. doi: 10.1093
  4. de Vallière C, Cosin-Roger J, Simmen S, Atrott K, Melhem H, Zeitz J, Madanchi M, Tcymbarevich I, Fried M, Kullak-Ublick GA, Vavricka SR, Misselwitz B, Seuwen K, Wagner CA, Eloranta JJ, Rogler G, Ruiz PA. Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein-Coupled Receptor OGR1 (GPR68). Cell Mol Gastroenterol Hepatol. 2016 Jun 25;2(6):796-810. doi: 10.1016/j.jcmgh.2016.06.003. eCollection 2016 Nov.
  5. Vavricka SR, Ruiz PA, Scharl S, Biedermann L, Scharl M, de Vallière C, Lundby C, Wenger RH, Held L, Merz TM, Gassmann M, Lutz T, Kunz A, Bron D, Fontana A, Strauss L, Weber A, Fried M, Rogler G, Zeitz J. Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. BMJ Open. 2017 Jan 5;7(1):e013477. doi: 10.1136/bmjopen-2016-013477.
  6. Greuter T, Schmidlin S, Lattmann J, Stotz M, Lehmann R, Zeitz J, Scharl M, Misselwitz B, Pohl D, Fried M, Tutuian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L, Vavricka SR. The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. Dig Liver Dis. 2017 Mar;49(3):268-272. doi: 10.1016/j.dld.2016.11.016
  7. Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, Frei P, Vavricka SR, Fried M, Rogler G, Scharl M. Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2017 Mar;29(3):322-330. doi: 10.1097/MEG.0000000000000783.
  8. Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Rogler G, Safroneeva E, Ali RA, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR; Swiss IBD Cohort Study Group. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation and anti-TNF Treatment. J Pediatr Gastroenterol Nutr. 2016 Oct 31.
  9. Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Raselli T, Frey-Wagner I, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, Scharl M. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J Clin Invest. 2016 Nov 1;126(11):4388. doi: 10.1172/JCI90897.
  10. Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-Brondolo V, Seibold F, Rogler G,Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Nov;22(11):2733-2747.
  11. Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Pittet V, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. Prediction of low bone mineral density in patients with inflammatory bowel diseases. United European Gastroenterol J. 2016 Oct;4(5):669-676. Epub 2016 Jun 30.
  12. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, Adamina M, Ardizzone S, Buskens CJ, Sebastian S, Laureti S, Sampietro GM, Vucelic B, van der Woude CJ, Barreiro-de Acosta M, Maaser C, Portela F, Vavricka SR, Gomollón F; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017 Feb;11(2):135-149. doi: 10.1093/ecco-jcc/jjw169.
  13. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka SR, Gionchetti P; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168.
  14. Vavricka SR, Stelzer T, Lattmann J, Stotz M, Lehmann R, Zeitz J, Scharl M, Misselwitz B, Pohl D, Fried M, Tutuian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L, Greuter T. Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. J Clin Gastroenterol. 2016 Sep 15. [Epub ahead of print]
  15. Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, Nydegger A, Vavricka SR, Moradpour D, Schoepfer AM; Swiss IBD Cohort Study Group. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol. 2017 Jan;29(1):91-97.
  16. Protic M, Schoepfer A, Yawalkar N, Vavricka SR, Seibold F. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels. Scand J Gastroenterol. 2016 Dec;51(12):1482-1488. Epub 2016 Aug 18.
  17. Bontà J, Zeitz J, Frei P, Biedermann L, Sulz MC, Vavricka SR, Scharl S, Fried M, Rogler G, Scharl M. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience. Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1329-34. doi: 10.1097/MEG.000000000716.
  18. Spalinger MR, Zeitz J, Biedermann L, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, Scharl M; Swiss IBD Cohort Study Group. Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. PLoS One. 2016 Jul 28;11(7):e0160215. doi: 10.1371/journal.pone.0160215.
  19. Vavricka SR, Vadasz N, Stotz M, Lehmann R, Studerus D, Greuter T, Frei P, Zeitz J, Scharl M, Misselwitz B, Pohl D, Fried M, Tutuian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L. Celiac disease diagnosis still significantly delayed - Doctor's but not patients' delay responsive for the increased total delay in women. Dig Liver Dis. 2016 Oct;48(10):1148-54. doi: 10.1016/j.dld.2016.06.016.
  20. Zeitz J, Ak M, Müller-Mottet S, Scharl S, Biedermann L, Fournier N, Frei P, Pittet V, Scharl M, Fried M, Rogler G, Vavricka S; Swiss IBD Cohort Study Group.. Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. PLoS One. 2016 Jun 22;11(6):e0156666. doi: 10.1371/journal.pone.0156666.
  21. Madanchi M, Zeitz J, Barthel C, Samaras P, Scharl S, Sulz MC, Biedermann L, Frei P, Vavricka SR, Rogler G, Scharl M. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. Digestion. 2016;94(1):1-8. doi: 10.1159/000447259. Epub 2016 Jun 18.
  22. Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PLoS One. 2016 May 23;11(5):e0155218. doi: 10.1371/journal.pone.0155218.
  23. Alatri A, Schoepfer A, Fournier N, Engelberger RP, Safroneeva E, Vavricka SR, Biedermann L, Calanca L, Mazzolai L; Swiss IBD Cohort Study Group. Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort. Scand J Gastroenterol. 2016 Oct;51(10):1200-5. doi: 10.1080/00365521.2016.1185464.
  24. Schoepfer AM, Vavricka SR, Safroneeva E, Fournier N, Manser C, Frei P, Deltenre P, Rogler G, Straumann A, Ezri J, Nydegger A, Braegger C. Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):245-247. doi: 10.1097/MPG.0000000000001238.
  25. Manser CN, Borovicka J, Seibold F, Vavricka SR, Lakatos PL, Fried M, Rogler G; investigators of the Swiss Inflammatory Bowel Disease Cohort Study. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J. 2016 Apr;4(2):281-7. doi: 10.1177/2050640615627533
  26. Sauter M, Keilholz G, Kranzbühler H, Lombriser N, Prakash M, Vavricka SR, Misselwitz B. Presenting symptoms predict local staging of anal cancer: a retrospective analysis of 86 patients. BMC Gastroenterol. 2016 Apr 6;16:46. doi: 10.1186/s12876-016-0461-0.
  27. Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, Scharl M. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J Clin Invest. 2016 May 2;126(5):1783-800. doi: 10.1172/JCI83669.
  28. Vavricka SR, Rogler G, Biedermann L. High Altitude Journeys, Flights and Hypoxia: Any Role for Disease Flares in IBD Patients? Dig Dis. 2016;34(1-2):78-83. doi: 10.1159/000442932. Epub 2016 Mar 16.
  29. Spalinger MR, Voegelin M, Biedermann L, Zeitz J, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, Scharl M; Swiss IBD Cohort Study Group The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. Digestion. 2016;93(3):182-92. doi: 10.1159/000444479.
  30. Vegh Z, Kurti Z, Gonczi L, Golovics PA, Lovasz BD, Szita I, Balogh M, Pandur T, Vavricka SR, Rogler G, Lakatos L, Lakatos PL. Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016 Jul;51(7):848-54. doi: 10.3109/00365521.2016.1140807.
  31. Vavricka SR, Sulz MC, Degen L, Rechner R, Manz M, Biedermann L, Beglinger C, Peter S, Safroneeva E, Rogler G, Schoepfer AM. Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. Endoscopy. 2016 Mar;48(3):256-62. doi: 10.1055/s-0035-1569674.
  32. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, De Vos M, De Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, Carbonnel F; European Crohn's and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Mar;10(3):239-54. doi: 10.1093/ecco-jcc/jjv213.
  33. Rogler G, Vavricka SR, Biedermann L. Integrating Imaging into Clinical Practice in Inflammatory Bowel Disease. Dig Dis. 2015 Sep 14;33 Suppl 1:37-43.
  34. Zimmermann K, Bastidas S, Knecht L, Kuster H, Vavricka SR, Günthard HF, Oxenius A. Gut commensal microbes do not represent a dominant antigenic source for continuous CD4+ T-cell activation during HIV-1 infection. Eur J Immunol. 2015 Sep 8. doi: 10.1002/eji.201545940.
  35. Giriens B, Yan P, Safroneeva E, Zwahlen M, Reinhard A, Nydegger A, Vavricka SR, Sempoux C, Straumann A, Schoepfer AM. Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993-2013: a population-based study. Allergy. 2015 Aug 25. doi: 10.1111/all.12733.
  36. Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Aliment Pharmacol Ther. 2015 Oct;42(8):977-89.
  37. Barthel C, Wiegand S, Scharl S, Scharl M, Frei P, Vavricka SR, Fried M, Sulz MC, Wiegand N, Rogler G, Biedermann L. Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. Nutr J. 2015 Aug 12;14:78.
  38. Vavricka SR, Greuter T, Scharl M, Mantzaris G, Shitrit AB, Filip R, Karmiris K, Thoeringer CK, Boldys H, Wewer AV, Yanai H, Flores C, Schmidt C, Kariv R, Rogler G, Rahier JF; ECCO CONFER investigators. Cogan's Syndrome in Patients With Inflammatory Bowel Disease - A Case Series. J Crohns Colitis. 2015 Oct;9(10):886-90.
  39. Safroneeva E, Vavricka SR, Fournier N, Seibold F, Mottet C, Nydegger A, Ezri J, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Aliment Pharmacol Ther. 2015 Sep;42(5):540-8.
  40. Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015 Aug;21(8):1794-800.
  41. Biedermann L, Fournier N, Misselwitz B, Frei P, Zeitz J, Manser CN, Pittet V, Juillerat P, von Känel R, Fried M, Vavricka SR, Rogler G; Swiss Inflammatory Bowel Disease Cohort Study Group. High Rates of Smoking Especially in Female Crohn's Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation-Data from the Swiss IBD Cohort Study. J Crohns Colitis. 2015 Oct;9(10):819-29.
  42. Safroneeva E, Vavricka SR, Fournier N, Straumann A, Rogler G, Schoepfer AM. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2015 Jun;21(6):1348-58.
  43. Hasler S, Zahnd N, Müller S, Vavricka SR, Rogler G, Tandjung R, Rosemann T. VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study. BMJ Open. 2015 Mar 10;5(3):e007306.
  44. Spalinger MR, Kasper S, Chassard C, Raselli T, Frey-Wagner I, Gottier C, Lang S, Atrott K, Vavricka SR, Mair F, Becher B, Lacroix C, Fried M, Rogler G, Scharl M. PTPN2 controls differentiation of CD4⁺ T cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal Immunol. 2015 Jul;8(4):918-29.
  45. Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. Addressing current treatment challenges in Crohn's disease in real life: a physician's survey. Dig Liver Dis. 2014 Dec;46(12):1066-71.
  46. Gao B, Vavricka SR, Meier PJ, Stieger B. Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS. Pflugers Arch. 2015 Jul;467(7):1481-93.
  47. Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM; Swiss Inflammatory Bowel Diseases Cohort Study Group. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. Scand J Gastroenterol. 2014 Oct;49(10):1207-18
  48. Biedermann L, Brülisauer K, Zeitz J, Frei P, Scharl M, Vavricka SR, Fried M, Loessner MJ, Rogler G, Schuppler M. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis. 2014 Sep;20(9):1496-501.
  49. Manser CN, Frei P, Grandinetti T, Biedermann L, Mwinyi J, Vavricka SR, Schoepfer A, Fried M, Rogler G; Investigators of the Swiss IBD Cohort Study. Risk factors for repetitive ileocolic resection in patients with Crohn's disease: results of an observational cohort study. Inflamm Bowel Dis. 2014 Sep;20(9):1548-54.
  50. Wojtal KA, Cee A, Lang S, Götze O, Frühauf H, Geier A, Pastor-Anglada M, Torres-Torronteras J, Martí R, Fried M, Lutz TA, Maggiorini M, Gassmann M, Rogler G, Vavricka SR. Downregulation of duodenal SLC transporters and activation of proinflammatory signaling constitute the early response to high altitude in humans. Am J Physiol Gastrointest Liver Physiol. 2014 Oct 1;307(7):G673-88.
  51. Frei P, Misselwitz B, Prakash MK, Schoepfer AM, Prinz Vavricka BM, Müllhaupt B, Fried M, Lehmann K, Ammann RW, Vavricka SR. Late biliary complications in human alveolar echinococcosis are associated with high mortality. World J Gastroenterol. 2014 May 21;20(19):5881-8.
  52. Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka SR, Rogler G, Frei P. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis. 2014 Nov;8(11):1427-37. Impact factor 2014: 6.234
  53. Kuchen T, Straumann A, Safroneeva E, Romero Y, Bussmann C, Vavricka SR, Netzer P, Reinhard A, Portmann S, Schoepfer AM. Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis. Allergy. 2014 Sep;69(9):1248-54.
  54. Barthel C, Biedermann L, Frei P, Vavricka SR, Kündig T, Fried M, Rogler G, Scharl M. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies. Digestion. 2014;89(3):209-15.
  55. Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena FD, Moum B, Vavricka SR, Schröder O, Herrmann E, Blumenstein I. Prevalence of Anemia in Inflammatory Bowel Diseases in European Countries: A Systematic Review and Individual Patient Data Meta-analysis.
  56. Inflamm Bowel Dis. 2014 Feb 25.
  57. Vavricka SR, Manser CN, Hediger S, Vögelin M, Scharl M, Biedermann L, Rogler S, Seibold F, Sanderink R, Attin T, Schoepfer A, Fried M, Rogler G, Frei P. Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013; 19:2768-77.
  58. Frei SM, Pesch T, Lang S, Weber A, Jehle E, Vavricka SR, Fried M, Rogler G, Scharl M. A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohn's disease-associated fistulae. Inflamm Bowel Dis. 2013;19:2878-87.
  59. Wolfram L, Fischbeck A, Frey-Wagner I, Wojtal KA, Lang S, Fried M, Vavricka SR, Hausmann M, Rogler G. Regulation of the expression of chaperone gp96 in macrophages and dendritic cells. PLoS One. 2013; 16;8:e76350.
  60. Spalinger MR, Lang S, Vavricka SR, Fried M, Rogler G, Scharl M. Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy. PLoS One. 2013; 8:e72384.
  61. Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR; IBD Cohort Study Group. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013; 108:1744-53
  62. Vavricka SR, Rogler G, Maetzler S, Misselwitz B, Safroneeva E, Frei P, Manser CN, Biedermann L, Fried M, Higgins P, Wojtal KA, Schoepfer AM. High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. J Crohns Colitis. 2014; 8:191-9.
  63. Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Känel R, Vavricka SR, Meyenberger C, Sagmeister M; on behalf of the members of the Swiss IBD Cohort Study Group. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study. Eur J Gastroenterol Hepatol. 2013 Apr 8. [Epub ahead of print]
  64. Wojtal KA, Wolfram L, Frey-Wagner I, Lang S, Scharl M, Vavricka SR, Rogler G.
  65. The effects of vitamin A on cells of innate immunity in vitro. Toxicol In Vitro. 2013; 27:1525-1532.
  66. Biedermann L, Zeitz J, Mwinyi J, Sutter-Minder E, Rehman A, Ott SJ, Steurer-Stey C, Frei A, Frei P, Scharl M, Loessner MJ, Vavricka SR, Fried M, Schreiber S, Schuppler M, Rogler G. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One. 2013; 8:e59260.
  67. Siebert U, Wurm J, Gothe RM, Arvandi M, Vavricka SR, von Känel R, Begré S, Sulz MC, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group. Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study. Inflamm Bowel Dis. 2013; 19:847-55.
  68. Vavricka SR, Schoepfer AM, Safroneeva E, Rogler G, Schwenkglenks M, Achermann R. A Shift From oral to intravenous iron supplementation therapy is observed over time in a large Swiss Cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19:840-6.
  69. Zeitz J, Schmidinger I, Rentsch K, Rogler G, Vavricka S. [Meulengracht disease]. Praxis (Bern 1994). 2013 Jan 30;102(3):129-35.
  70. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR. Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes. Inflamm Bowel Dis. 2013; 19: 332-341.
  71. Wojtal KA, Rogler G, Scharl M, Biedermann L, Frei P, Fried M, Weber A, Eloranta JJ, Kullak-Ublick GA, Vavricka SR. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS One. 2012; 7: e43361.
  72. Wildi SM, Schoepfer AM, Vavricka SR, Fruehauf H, Safroneeva E, Wiegand N, Bauerfeind P, Fried M. Colorectal polypectomy during insertion and withdrawal or only during withdrawal? A randomized controlled trial. Endoscopy. 2012; 44: 1019-23.
  73. Biedermann L, Mwinyi J, Scharl M, Frei P, Zeitz J, Kullak-Ublick GA, Vavricka SR, Fried M, Weber A, Humpf HU, Peschke S, Jetter A, Krammer G, Rogler G. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - An open pilot study. J Crohns Colitis. 2013; 7:271-9.
  74. Frei-Lanter CM, Vavricka SR, Kruger TH, Tutuian R, Geier A, Bauerfeind P, Krones T, Fried M, Frei P. Endoscopy for repeatedly ingested sharp foreign bodies in patients with borderline personality disorder: an international survey. Eur J Gastroenterol Hepatol. 2012; 24: 793-7.
  75. Schoepfer AM, Vavricka SR, Zahnd-Straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis. 2012; 6: 412-8.
  76. Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 496-505.
  77. Scharl M, Wojtal KA, Becker HM, Fischbeck A, Frei P, Arikkat J, Pesch T, Kellermeier S, Boone DL, Weber A, Loessner MJ, Vavricka SR, Fried M, McCole DF, Rogler G. Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. Inflamm Bowel Dis. 2012; 18: 1287-302.
  78. Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M; for the Swiss IBDnet and the Swiss IBD Cohort Study Group. Systematic assessment of factors influencing preferences of crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012; 18: 1523-30.
  79. Eloranta JJ, Wenger C, Mwinyi J, Hiller C, Gubler C, Vavricka SR, Fried M, Kullak-Ublick GA; Swiss IBD Cohort Study Group. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics. 2011; 21: 559-64.
  80. Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V; Swiss IBD Cohort Study Group. Epidemiology of inflammatory bowel disease: Is there a shift towards onset at a younger age? J Pediatr Gastroenterol Nutr. 2011; 53: 141-4.
  81. Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis. 2011; 17: 1530-9.
  82. Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM; the Swiss IBD Cohort Study Group. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 496-505.
  83. Scharl M, Frei P, Fried M, Rogler G, Vavricka SR. Association between Cogan's syndrome and inflammatory bowel disease: a case series. J Crohns Colitis. 2011; 5: 64-8.
  84. Oberacher M, Pohl D, Vavricka SR, Fried M, Tutuian R. Diagnosing lactase deficiency in three breaths. Eur J Clin Nutr. 2011; 65: 614-8.
  85. Heinrich H, Goetze O, Menne D; Iten PX, Friehauf H, Vavricka SR, Schwizer W, Fried M, Fox M. Effects on gastric function and symptoms of drinking wine, black tea, or schnapps with a Swiss cheese fondue: randomised controlled crossover trial. BMJ 2010; 14: 341.
  86. Voegtlin M, Vavricka SR, Schopfer AM, Straumann A, Voegtlin J, Rogler R, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C; Swiss IBD Cohort Study. Prevalence of anemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohn Colitis 2010; 4; 642-8.
  87. Scharl M, McCole DF, Weber A, Vavricka SR, Frei P, Kellermeier S; Pesch T, Fried M; Rogler G. Protein tyrosine phosphatase N2 regulates TNF-alpha-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut 2011; 60: 189-97.
  88. Scharl M, Geisel S, Vavricka SR, Rogler G. Dying in Yoghurt: The Number of Living Bacteria in Probiotic Yoghurt Decreases under Exposure to Room Temperature. Digestion. 2010; 83:13-17.
  89. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM. Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort. Am J Gastroenterol. 2011; 106: 110-9.
  90. Vavricka SR, Tutuian R, Imhof A, Wildi S, Gubler C, Fruehauf H, Ruef C, Schoepfer AM, Fried M. Air suctioning during colon biopsy forceps removal reduces bacterial air contamination in the endoscopy suite. Endoscopy. 2010; 42: 736-41.
  91. Fries C, Roos M, Gaspert A, Vogt P, Salomon F, Wüthrich RP, Vavricka SR, Fehr T. Atheroembolic disease--a frequently missed diagnosis: results of a 12-year matched-pair autopsy study. Medicine (Baltimore). 2010; 89:126-32.
  92. Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther. 2010; 31: 1286-95.
  93. Nichita C, Stelle M, Vavricka SR, El-Wafa Ali A, Ballabeni P, de Saussure P, Straumann A, Rogler G, Michetti P. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion. 2010; 8: 78-85.
  94. Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. Inflamm Bowel Dis. 2010;16:933-8.
  95. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI. Am J Gastroenterol.2010; 105: 162-9.
  96. Lee J, Tattoli I, Wojtal KA, Vavricka SR, Philpott DJ, Girardin SE. pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. J Biol Chem. 2009; 284: 23818-29.
  97. Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, Beglinger C, Fried M, Kullak-Ublick GA, Vavricka SR. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab Dispos. 2009; 37:1871-7.
  98. Vavricka SR, Manz M, Burri E. Trichuris trichiura (Whipworm). Clin Gastroenterol Hepatol. 2009; 7:A16.
  99. Gruber D, Pohl D, Vavricka SR, Stutz B, Fried M, Tutuian R. Swiss tertiary care center experience challenges the age-cohort effect in Helicobacter pylori infection. J Gastrointestin Liver Dis. 2008; 17:373-7.
  100. Manz M, Beglinger C, Vavricka SR. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy. Gut. 2009;58:149.
  101. Burri E, Nüesch R, Lugli A, Noll P, Vavricka SR. [Early gastric cancer--or not] Praxis (Bern 1994). 2008; 97:1351-5.
  102. Hochholzer W, Vavricka SR, Stussi G, Adams H, Wruk D, Battegay E, Zimmerli LU. [Diffuse abdominal pain and eosinophilia] Internist (Berl). 2008; 49:1379-82.
  103. Vavricka SR, Dirnhofer S, Degen L. Polyarteritis nodosa mimicking inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007 Nov;5(11):A22.
  104. Wildi SM, Gubler C, Vavricka SR, Fried M, Bauerfeind P. Transnasal endoscopy for the placement of nasoenteral feeding tubes: does the working length of the endoscope matter? Gastrointest Endosc. 2007; 66: 225-9.
  105. Ismair MG, Kullak-Ublick GA, Blakely RD, Fried M, Vavricka SR. Tegaserod inhibits the serotonin transporter SERT. Digestion. 2007; 75: 90-5.
  106. Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, Kullak-Ublick GA, Vavricka SR. Regional distribution of solute carrier (SLC) mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007; 35: 590-594.
  107. Carlson RM, Vavricka SR, Eloranta JJ, Musch MW, Arvans DL, Kles KA, Walsh-Reitz MM, Kullak-Ublick GA, Chang EB. fMLP Induces Hsp27 Expression and Confers Intestinal Epithelial Cell Protection. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1070-G1078.
  108. Ismair MG, Vavricka SR, Kullak-Ublick GA, Fried M, Mengin-Lecreulx D, Girardin SE. hPepT1 selectively transports muramyl dipeptide but not Nod1-activating muramyl peptides. Can Journal Physiol Pharm 2006; 84:1313-1319.
  109. Vavricka SR, Storck CA, Wildi SM, Tutuian R, Wiegand N, Rousson V, Fruehauf H, Fried M, Mullhaupt B. Limited diagnostic value of laryngopharyngeal lesions in patients with gastroesophageal reflux during routine upper gastrointestinal endoscopy. Am J Gastroenterol 2007; 102: 716-22.
  110. Gubler C, Bauerfeind P, Vavricka SR, Mullhaupt B, Fried M, Wildi SM. Bedside sonographic position control of enteral feeding tubes. A controlled study in intensive care unit patients. Endoscopy 2006; 38:1256-1260.
  111. Landrier JF, Eloranta JJ, Vavricka, SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am J Physiol Gastrointest Liver Physiol 2006; 290:G476-85.
  112. Vavricka SR, Musch MW, Fujiya M, Kles K, Chang L, Eloranta JJ, Kullak-Ublick GA, Drabik K, Merlin D, Chang EB. Tumor necrosis factor-alpha and interferon-gamma increase PepT1 expression and activity in the human colon carcinoma cell line Caco2/bbe and mouse intestine. Pflugers Arch 2005; 19:1-10.
  113. Kles KA, Vavricka SR, Turner JR, Musch MW, Hanauer SB, Chang EB. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis 2005; 11:253-257.
  114. Gao B, Huber RD, Wenzel A, Vavricka SR, Ismair MG, Reme C, Meier PJ. Localization of organic anion transporting polyppeptides in the rat and human ciliary body epithelium. Exp Eye Res 2005; 80:61-72.
  115. Arvans DL, Vavricka SR, Ren H. Musch MW, Kang L, Rocha FG, Lucioni A, Turner JR, Alverdy J, Chang EB. Luminal bacterial flora determines physiological expression of intestinal epithelial cytoprotective heat shock proteins 25 and 72. Am J Physiol Gastrointest Liver Physiol 2005; 288:G696-704.
  116. Vavricka SR, Musch MW, Chang JE, Nakagawa Y, Phanvijhitsiri K, Waypa TS, Merlin D, Schneewind O, Chang EB. HPepT1 transports muramyl dipeptide activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 2004; 127:1401-1409.
  117. Vavricka SR, Halter J, Hechelhammer L, Himmelmann A. Pneumocystis carinii pneumonia in chronic lymphocytic leukemia. Postgrad Med J 2004; 80:236-238
  118. Prinz BM, Vavricka SR, Graf P, Burg G, Dummer R. Efficacy of laser treatment of tattoos using lasers emitting wavelengths of 532nm, 755nm, and 1064 nm. Br J Dermatol 2004; 150:245-251.
  119. Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3 beta in hepatocellular carcinoma. J Hepatol 2004; 40:212.
  120. Vavricka SR, Walter RB, Irani S, Halter J, Schanz U. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. Ann Hematol. 2003 Sep;82(9):570-3.
  121. Theurillat JP, Vavricka SR, Went P, Weishaupt D, Perren A, Leonard-Meier C, Bachli EB. Morphologic changes and altered gene expression in an epithelioid hemangioendothelioma during a ten-year course of disease. Pathol Res Pract 2003; 199:165-170.
  122. Vavricka SR, Wettstein T, Speich R, Gaspert A, Bachli EB. Pulmonary granuloma after tumor necrosis factor alpha antagonist therapy. Thorax 2003; 58:278-279.
  123. Bachli EB, Vavricka SR, Walter RB, Leschinger MI, Maggiorini M. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Med 2003; 29:337.
  124. Vavricka SR, Himmelmann A, Schaffner A. Brugada syndrome. Lancet 2002; 360:1913.
  125. Vavricka SR, Walter RB, Brandle M, Ballmer PE, Haller A. Diabetic ketoacidosis and hyperosmolar hyperglycemia. 24 consecutive cases. Dtsch Med Wochenschr 2002; 127: 2441-2446.
  126. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002; 132:316-320.
  127. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattiger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36:164-172.
  128. Vavricka SR, Halter J, Furrer K, Wolfensberger U, Schanz U. Contrast media triggering cutaneous graft-versus-host disease. Bone Marrow Transplant 2002; 29:899-901.
  129. Husarik D, Vavricka SR, Mark M, Schaffner A, Walter RB. Assessment of digital clubbing in medical inpatients by digital photography and computerized analysis. Swiss Med Wkly 2002; 132:132-138.
  130. Gao B, Wenzel A, Grimm C, Vavricka SR, Benke D, Meier PJ, Reme CE. Localization of organic anion transport protein 2 in the apical region of rat retinal pigment epithelium. Invest Opthalmol Vis Sci 2002; 43:510-514.